MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors
Open Access
- 15 February 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (10), 2714-2729
- https://doi.org/10.1158/0008-5472.can-20-2370
Abstract
This study provides key insights into the potential for using MEKi combined with PARPi and anti-PD-L1 for the treatment of all mutant KRAS tumors.Keywords
Other Versions
Funding Information
- Nature and Science Foundation of China (81572569, 81874106)
- National Key R&D Program of China (2016YFC1303100)
- Nature and Science Foundation of China (81402163, 81974408)
- NIH (P50CA217685, U01 CA217842)
- Ovarian Cancer Research Foundation
This publication has 49 references indexed in Scilit:
- cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STINGNature, 2013
- HIV Downregulates Interferon-Stimulated Genes in Primary MacrophagesJournal of Interferon & Cytokine Research, 2013
- Tumor-Infiltrating γδ T Lymphocytes Predict Clinical Outcome in Human Breast CancerThe Journal of Immunology, 2012
- Triepitopic Antibody Fusions Inhibit Cetuximab-Resistant BRAF and KRAS Mutant Tumors via EGFR Signal RepressionJournal of Molecular Biology, 2012
- Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPβ Transcription FactorImmunity, 2010
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation CarriersThe New England Journal of Medicine, 2009
- FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survivalLeukemia, 2007
- The emerging role of lysophosphatidic acid in cancerNature Reviews Cancer, 2003
- Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous CarcinomaJNCI Journal of the National Cancer Institute, 2003
- Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion frontOncogene, 2001